Skip to content
Open in App
Sanofi DRC logo

Sanofi DRC

web2

Sanofi engages in the research, development, manufacture, and marketing of therapeutic solution...

Symbol · SNY
Company profile

About

Sanofi engages in the research, development, manufacture, and marketing of therapeutic solutions. It provides immunology and inflammation, rare diseases neurology, oncology, and other vaccines. It also offers poliomyelitis, pertussis, and haemophilus influenzae type b (Hib) pediatric vaccines; respiratory syncytial virus protection and hexavalent combination vaccines that includes hepatitis A, typhoid, yellow fever, and rabies vaccines. It has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301 for treatment of alpha-synucleinopathies; and Innate Pharma SA for cell engager program targeting B7-H3. Further, it has a collaboration agreements with Atomwise to use ATOMNET platform and Insilico Medicine to use Pharma.AI, a medicine’s AI platform; Kymera Therapeutics, Inc. to develop and commercialize protein degrader therapies targeting IRAK4 in patients with immune-inflammatory diseases; Nurix Therapeutics, Inc. to develop protein degradation therapies; Denali Therapeutics Inc. to treat systemic inflammatory diseases, such as ulcerative colitis; and Adagene Inc. for development of antibody-based therapies. Additionally, it has a collaboration with Scribe Therapeutics Inc. to develop genome editing technologies; Teva Pharmaceuticals to co-develop and co-commercialize TEV’574, for treatment of ulcerative colitis and Crohn’s disease; and co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was incorporated in 1994 and is headquartered in Paris, France.

Explore by sector

Explore this sector

Market identity

Exchange listings

Listing identities only. Orbitrum does not publish live prices or market performance on this public profile.

Progress

Roadmap

Belén Garijo to take office as Chief Executive Officer

KEY STEP

Sanofi announced that Belén Garijo will take up her duties as Chief Executive Officer at the end of the company Annual General Meeting scheduled for April 29, 2026, subject to the required shareholder approvals related to her appointment.

Roadmap reference

European Commission approves Cenrifki for secondary progressive multiple sclerosis

KEY STEP

The European Commission approved Cenrifki, also known as tolebrutinib, for adults with secondary progressive multiple sclerosis who had experienced no relapses during the previous two years. Sanofi stated that the approval was based on the HERCULES phase 3 study with supporting data from the GEMINI 1 and GEMINI 2 studies, and that commercial availability in Germany was planned.

Roadmap reference

Sanofi discontinues amlitelimab development in atopic dermatitis

KEY STEP

Sanofi announced on July 24, 2026 that amlitelimab would not progress to global regulatory review for atopic dermatitis after the company concluded that the total efficacy and safety evidence did not support further development and that the medicine would not provide a meaningful improvement over the standard of care.

Roadmap reference

New Sanofi Executive Committee structure takes effect

KEY STEP

Sanofi announced a more focused Executive Committee structure effective September 1, 2026. The structure includes Paulo Fontoura as Head of Research and Development and expands the Finance function to include Global Partnering and Business Development.

Roadmap reference
People

Company team

RD

Rachel Duan

Independent Director

Company leadership profile.

CD

Clotilde Delbos

Independent Director

Company leadership profile.

BG

Belen Garijo Lopez

CEO & Director

Company leadership profile.

FO

Frederic Oudea

Independent Chairman

Company leadership profile.

JD

Jean-François Dehecq

Honorary Chairman

Company leadership profile.

SW

Serge Weinberg

Honorary Chairman

Company leadership profile.

CF

Carole Ferrand

Independent Director

Company leadership profile.

CB

Christophe Babule

Director

Company leadership profile.

LK

Lise Kingo

Independent Director

Company leadership profile.

BL

Barbara Lavernos

Director

Company leadership profile.

WL

Wolfgang Laux

Employee Representative Director

Company leadership profile.

EV

Emile Voest

Independent Director

Company leadership profile.

AY

Antoine Yver

Independent Director

Company leadership profile.

AM

Anne-Francoise Michele Nesmes Rankine

Independent Director

Company leadership profile.

JS

John S. Sundy

Independent Director

Company leadership profile.

JK

Jean-Paul Kress

Independent Director

Company leadership profile.

HD

Humberto De Sousa

Employee Representative Director

Company leadership profile.

CH

Christel Heydemann

Independent Director

Company leadership profile.

Expert coverage

1 expert evaluated Sanofi DRC.

Orbitrum research

Experts evaluating Sanofi DRC

Explore the public profiles of experts who have evaluated this project.

Orbitrum Academy

Learn how to read a project assessment